<DOC>
	<DOC>NCT00832689</DOC>
	<brief_summary>The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.</brief_summary>
	<brief_title>Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Histologically or cytologically confirmed inoperable biliary tract cancer Age: 18 ~75 years old Performance status: ECOG 02 Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin No greater than 2 fold the upper normal limit AST/ALT : No greater than 3 fold the upper normal limit Renal: Creatinine no greater than 1.5 mg/dL Not pregnant No other serious medical or psychiatric illness that would preclude giving informed consent or limit No prior chemotherapy within 6 months No other concurrent anticancer radiotherapy within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>toxicity</keyword>
</DOC>